Gene Knockout Cell Line Construction Service refers to a specialized scientific service provided by biotechnology companies and research institutions, aimed at creating cell lines with specific genes intentionally disrupted or "knocked out." This service utilizes advanced gene editing technologies to delete or inactivate a target gene within the genome of a cell line, allowing researchers to study the gene's function, role in disease, or potential as a therapeutic target.
The global Gene Knockout Cell Line Construction Service market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淕ene Knockout Cell Line Construction Service Industry Forecast鈥� looks at past sales and reviews total world Gene Knockout Cell Line Construction Service sales in 2022, providing a comprehensive analysis by region and market sector of projected Gene Knockout Cell Line Construction Service sales for 2023 through 2029. With Gene Knockout Cell Line Construction Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Knockout Cell Line Construction Service industry.
This Insight Report provides a comprehensive analysis of the global Gene Knockout Cell Line Construction Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Gene Knockout Cell Line Construction Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Gene Knockout Cell Line Construction Service market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Knockout Cell Line Construction Service and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Knockout Cell Line Construction Service.
United States market for Gene Knockout Cell Line Construction Service is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Gene Knockout Cell Line Construction Service is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Gene Knockout Cell Line Construction Service is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Gene Knockout Cell Line Construction Service players cover OriGene, Creative Bioarray, Horizon Discovery, Synthego, Cyagen, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Gene Knockout Cell Line Construction Service market by product type, application, key players and key regions and countries.
Segmentation by Type:
CRISPR/Cas9
TALEN
Others
Segmentation by Application:
Academic and Research Institutions
Pharmaceutical and Biotechnology Companies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
CRISPR/Cas9
TALEN
Others
Segmentation by Application:
Academic and Research Institutions
Pharmaceutical and Biotechnology Companies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
OriGene
Creative Bioarray
Horizon Discovery
Synthego
Cyagen
Cellecta
BiologicsCorp
Kyinno Bio
Porton Advanced
Cytosurge
AcceGen
System Biosciences
Altogen Labs
Syd Labs
Lifeasible
GenScript
Ubigene
Beyotime
Abace Biotechnology
Viewsolid Biotechnology
iGeneBio
VectorBuilder
BrainVTA
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Gene Knockout Cell Line Construction Service 麻豆原创 Size 2019-2030
2.1.2 Gene Knockout Cell Line Construction Service 麻豆原创 Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Gene Knockout Cell Line Construction Service by Country/Region, 2019, 2023 & 2030
2.2 Gene Knockout Cell Line Construction Service Segment by Type
2.2.1 CRISPR/Cas9
2.2.2 TALEN
2.2.3 Others
2.3 Gene Knockout Cell Line Construction Service 麻豆原创 Size by Type
2.3.1 Gene Knockout Cell Line Construction Service 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Gene Knockout Cell Line Construction Service 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Gene Knockout Cell Line Construction Service Segment by Application
2.4.1 Academic and Research Institutions
2.4.2 Pharmaceutical and Biotechnology Companies
2.5 Gene Knockout Cell Line Construction Service 麻豆原创 Size by Application
2.5.1 Gene Knockout Cell Line Construction Service 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Gene Knockout Cell Line Construction Service 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Gene Knockout Cell Line Construction Service 麻豆原创 Size by Player
3.1 Gene Knockout Cell Line Construction Service 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Gene Knockout Cell Line Construction Service Revenue by Player (2019-2024)
3.1.2 Global Gene Knockout Cell Line Construction Service Revenue 麻豆原创 Share by Player (2019-2024)
3.2 Global Gene Knockout Cell Line Construction Service Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Gene Knockout Cell Line Construction Service by Region
4.1 Gene Knockout Cell Line Construction Service 麻豆原创 Size by Region (2019-2024)
4.2 Global Gene Knockout Cell Line Construction Service Annual Revenue by Country/Region (2019-2024)
4.3 Americas Gene Knockout Cell Line Construction Service 麻豆原创 Size Growth (2019-2024)
4.4 APAC Gene Knockout Cell Line Construction Service 麻豆原创 Size Growth (2019-2024)
4.5 Europe Gene Knockout Cell Line Construction Service 麻豆原创 Size Growth (2019-2024)
4.6 Middle East & Africa Gene Knockout Cell Line Construction Service 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Gene Knockout Cell Line Construction Service 麻豆原创 Size by Country (2019-2024)
5.2 Americas Gene Knockout Cell Line Construction Service 麻豆原创 Size by Type (2019-2024)
5.3 Americas Gene Knockout Cell Line Construction Service 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Gene Knockout Cell Line Construction Service 麻豆原创 Size by Region (2019-2024)
6.2 APAC Gene Knockout Cell Line Construction Service 麻豆原创 Size by Type (2019-2024)
6.3 APAC Gene Knockout Cell Line Construction Service 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Gene Knockout Cell Line Construction Service 麻豆原创 Size by Country (2019-2024)
7.2 Europe Gene Knockout Cell Line Construction Service 麻豆原创 Size by Type (2019-2024)
7.3 Europe Gene Knockout Cell Line Construction Service 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Gene Knockout Cell Line Construction Service by Region (2019-2024)
8.2 Middle East & Africa Gene Knockout Cell Line Construction Service 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Gene Knockout Cell Line Construction Service 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Gene Knockout Cell Line Construction Service 麻豆原创 Forecast
10.1 Global Gene Knockout Cell Line Construction Service Forecast by Region (2025-2030)
10.1.1 Global Gene Knockout Cell Line Construction Service Forecast by Region (2025-2030)
10.1.2 Americas Gene Knockout Cell Line Construction Service Forecast
10.1.3 APAC Gene Knockout Cell Line Construction Service Forecast
10.1.4 Europe Gene Knockout Cell Line Construction Service Forecast
10.1.5 Middle East & Africa Gene Knockout Cell Line Construction Service Forecast
10.2 Americas Gene Knockout Cell Line Construction Service Forecast by Country (2025-2030)
10.2.1 United States 麻豆原创 Gene Knockout Cell Line Construction Service Forecast
10.2.2 Canada 麻豆原创 Gene Knockout Cell Line Construction Service Forecast
10.2.3 Mexico 麻豆原创 Gene Knockout Cell Line Construction Service Forecast
10.2.4 Brazil 麻豆原创 Gene Knockout Cell Line Construction Service Forecast
10.3 APAC Gene Knockout Cell Line Construction Service Forecast by Region (2025-2030)
10.3.1 China Gene Knockout Cell Line Construction Service 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Gene Knockout Cell Line Construction Service Forecast
10.3.3 Korea 麻豆原创 Gene Knockout Cell Line Construction Service Forecast
10.3.4 Southeast Asia 麻豆原创 Gene Knockout Cell Line Construction Service Forecast
10.3.5 India 麻豆原创 Gene Knockout Cell Line Construction Service Forecast
10.3.6 Australia 麻豆原创 Gene Knockout Cell Line Construction Service Forecast
10.4 Europe Gene Knockout Cell Line Construction Service Forecast by Country (2025-2030)
10.4.1 Germany 麻豆原创 Gene Knockout Cell Line Construction Service Forecast
10.4.2 France 麻豆原创 Gene Knockout Cell Line Construction Service Forecast
10.4.3 UK 麻豆原创 Gene Knockout Cell Line Construction Service Forecast
10.4.4 Italy 麻豆原创 Gene Knockout Cell Line Construction Service Forecast
10.4.5 Russia 麻豆原创 Gene Knockout Cell Line Construction Service Forecast
10.5 Middle East & Africa Gene Knockout Cell Line Construction Service Forecast by Region (2025-2030)
10.5.1 Egypt 麻豆原创 Gene Knockout Cell Line Construction Service Forecast
10.5.2 South Africa 麻豆原创 Gene Knockout Cell Line Construction Service Forecast
10.5.3 Israel 麻豆原创 Gene Knockout Cell Line Construction Service Forecast
10.5.4 Turkey 麻豆原创 Gene Knockout Cell Line Construction Service Forecast
10.6 Global Gene Knockout Cell Line Construction Service Forecast by Type (2025-2030)
10.7 Global Gene Knockout Cell Line Construction Service Forecast by Application (2025-2030)
10.7.1 GCC Countries 麻豆原创 Gene Knockout Cell Line Construction Service Forecast
11 Key Players Analysis
11.1 OriGene
11.1.1 OriGene Company Information
11.1.2 OriGene Gene Knockout Cell Line Construction Service Product Offered
11.1.3 OriGene Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 OriGene Main Business Overview
11.1.5 OriGene Latest Developments
11.2 Creative Bioarray
11.2.1 Creative Bioarray Company Information
11.2.2 Creative Bioarray Gene Knockout Cell Line Construction Service Product Offered
11.2.3 Creative Bioarray Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Creative Bioarray Main Business Overview
11.2.5 Creative Bioarray Latest Developments
11.3 Horizon Discovery
11.3.1 Horizon Discovery Company Information
11.3.2 Horizon Discovery Gene Knockout Cell Line Construction Service Product Offered
11.3.3 Horizon Discovery Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Horizon Discovery Main Business Overview
11.3.5 Horizon Discovery Latest Developments
11.4 Synthego
11.4.1 Synthego Company Information
11.4.2 Synthego Gene Knockout Cell Line Construction Service Product Offered
11.4.3 Synthego Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Synthego Main Business Overview
11.4.5 Synthego Latest Developments
11.5 Cyagen
11.5.1 Cyagen Company Information
11.5.2 Cyagen Gene Knockout Cell Line Construction Service Product Offered
11.5.3 Cyagen Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Cyagen Main Business Overview
11.5.5 Cyagen Latest Developments
11.6 Cellecta
11.6.1 Cellecta Company Information
11.6.2 Cellecta Gene Knockout Cell Line Construction Service Product Offered
11.6.3 Cellecta Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Cellecta Main Business Overview
11.6.5 Cellecta Latest Developments
11.7 BiologicsCorp
11.7.1 BiologicsCorp Company Information
11.7.2 BiologicsCorp Gene Knockout Cell Line Construction Service Product Offered
11.7.3 BiologicsCorp Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 BiologicsCorp Main Business Overview
11.7.5 BiologicsCorp Latest Developments
11.8 Kyinno Bio
11.8.1 Kyinno Bio Company Information
11.8.2 Kyinno Bio Gene Knockout Cell Line Construction Service Product Offered
11.8.3 Kyinno Bio Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Kyinno Bio Main Business Overview
11.8.5 Kyinno Bio Latest Developments
11.9 Porton Advanced
11.9.1 Porton Advanced Company Information
11.9.2 Porton Advanced Gene Knockout Cell Line Construction Service Product Offered
11.9.3 Porton Advanced Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Porton Advanced Main Business Overview
11.9.5 Porton Advanced Latest Developments
11.10 Cytosurge
11.10.1 Cytosurge Company Information
11.10.2 Cytosurge Gene Knockout Cell Line Construction Service Product Offered
11.10.3 Cytosurge Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Cytosurge Main Business Overview
11.10.5 Cytosurge Latest Developments
11.11 AcceGen
11.11.1 AcceGen Company Information
11.11.2 AcceGen Gene Knockout Cell Line Construction Service Product Offered
11.11.3 AcceGen Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 AcceGen Main Business Overview
11.11.5 AcceGen Latest Developments
11.12 System Biosciences
11.12.1 System Biosciences Company Information
11.12.2 System Biosciences Gene Knockout Cell Line Construction Service Product Offered
11.12.3 System Biosciences Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 System Biosciences Main Business Overview
11.12.5 System Biosciences Latest Developments
11.13 Altogen Labs
11.13.1 Altogen Labs Company Information
11.13.2 Altogen Labs Gene Knockout Cell Line Construction Service Product Offered
11.13.3 Altogen Labs Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 Altogen Labs Main Business Overview
11.13.5 Altogen Labs Latest Developments
11.14 Syd Labs
11.14.1 Syd Labs Company Information
11.14.2 Syd Labs Gene Knockout Cell Line Construction Service Product Offered
11.14.3 Syd Labs Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.14.4 Syd Labs Main Business Overview
11.14.5 Syd Labs Latest Developments
11.15 Lifeasible
11.15.1 Lifeasible Company Information
11.15.2 Lifeasible Gene Knockout Cell Line Construction Service Product Offered
11.15.3 Lifeasible Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.15.4 Lifeasible Main Business Overview
11.15.5 Lifeasible Latest Developments
11.16 GenScript
11.16.1 GenScript Company Information
11.16.2 GenScript Gene Knockout Cell Line Construction Service Product Offered
11.16.3 GenScript Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.16.4 GenScript Main Business Overview
11.16.5 GenScript Latest Developments
11.17 Ubigene
11.17.1 Ubigene Company Information
11.17.2 Ubigene Gene Knockout Cell Line Construction Service Product Offered
11.17.3 Ubigene Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.17.4 Ubigene Main Business Overview
11.17.5 Ubigene Latest Developments
11.18 Beyotime
11.18.1 Beyotime Company Information
11.18.2 Beyotime Gene Knockout Cell Line Construction Service Product Offered
11.18.3 Beyotime Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.18.4 Beyotime Main Business Overview
11.18.5 Beyotime Latest Developments
11.19 Abace Biotechnology
11.19.1 Abace Biotechnology Company Information
11.19.2 Abace Biotechnology Gene Knockout Cell Line Construction Service Product Offered
11.19.3 Abace Biotechnology Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.19.4 Abace Biotechnology Main Business Overview
11.19.5 Abace Biotechnology Latest Developments
11.20 Viewsolid Biotechnology
11.20.1 Viewsolid Biotechnology Company Information
11.20.2 Viewsolid Biotechnology Gene Knockout Cell Line Construction Service Product Offered
11.20.3 Viewsolid Biotechnology Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.20.4 Viewsolid Biotechnology Main Business Overview
11.20.5 Viewsolid Biotechnology Latest Developments
11.21 iGeneBio
11.21.1 iGeneBio Company Information
11.21.2 iGeneBio Gene Knockout Cell Line Construction Service Product Offered
11.21.3 iGeneBio Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.21.4 iGeneBio Main Business Overview
11.21.5 iGeneBio Latest Developments
11.22 VectorBuilder
11.22.1 VectorBuilder Company Information
11.22.2 VectorBuilder Gene Knockout Cell Line Construction Service Product Offered
11.22.3 VectorBuilder Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.22.4 VectorBuilder Main Business Overview
11.22.5 VectorBuilder Latest Developments
11.23 BrainVTA
11.23.1 BrainVTA Company Information
11.23.2 BrainVTA Gene Knockout Cell Line Construction Service Product Offered
11.23.3 BrainVTA Gene Knockout Cell Line Construction Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.23.4 BrainVTA Main Business Overview
11.23.5 BrainVTA Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.